Cours suspendu

Communiqués Centessa Pharmaceuticals plc

Actions

CNTA

US1523091007

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 23/06/2026			Varia. 5j.	Varia. 1 janv.
40,50 ^USD	+0,80%		-.--%	+61,94%

24/06	Le Swiss Market Index prolonge son rally; l'action OC Oerlikon progresse	MT
24/06	Eli Lilly finalise l’acquisition de Centessa Pharmaceuticals	MT

Communiqués

22/06	Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales	GL
11/05	Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA	BU
01/04	Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA	BU
31/03	Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?	PR
31/03	CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders	BU
31/03	Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders	PR
12/02	Centessa Pharmaceuticals : February 2026 Corporate Overview (597223)	PU
03/02	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences	GL
03/02	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences	AQ
15/01	Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting	AQ
14/01	Centessa Pharmaceuticals : CNT-9982, an orexin receptor 2 agonist, enhances wakefulness in marmosets, and in the Wistar Kyoto rat model of major depressive disorder, normalizes the arousal state phenotype and alleviates behavioral despair (743a9b)	PU
14/01	Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting	GL
11/12	Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications	GL
02/12	Centessa Pharmaceuticals : December 2025 Corporate Overview (304466)	PU
12/11	Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares	GL
11/11	Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares	GL
07/11	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences	GL
05/11	Centessa Pharmaceuticals : November 2025 Corporate Overview (a6ee0e)	PU
05/11	Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program	GL
05/11	Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program	AQ
08/09/25	Centessa Pharmaceuticals : Development of a Novel, Oral Orexin Receptor 2 Agonist, ORX750, for Treatment of Patients With Narcolepsy (Type 1 and 2) and Idiopathic Hypersomnia (d78685)	PU
03/09/25	Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference	GL
03/09/25	Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference	AQ
12/08/25	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025	GL
17/06/25	Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application for ORX142, a Novel Orexin Receptor 2 Agonist, Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year	AQ